United Therapeutics Corporation (UTHR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Silver Spring, MD, 미국. 현재 CEO는 Martine A. Rothblatt.
UTHR 을(를) 보유 IPO 날짜 1999-06-17, 1,305 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $25.36B.
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with chronic and life-threatening diseases, particularly pulmonary hypertension and related conditions. The company's commercial portfolio includes Remodulin, Tyvaso, Orenitram, and Adcirca for treating pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. United Therapeutics maintains an active pipeline of innovative treatments including gene therapies, advanced drug delivery systems, and next-generation formulations, supported by strategic partnerships with leading medical device and pharmaceutical companies. Headquartered in Silver Spring, Maryland, the company operates globally to address significant unmet medical needs in pulmonary hypertension and oncology.
